Congress to pay pharma $6B for antibiotics—with no price caps
S. 4875 — PASTEUR Act of 2026 · Filed by Michael Bennet (D-CO) · 4 cosponsors · Introduced Jun 23, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a federal contract program to pay pharmaceutical companies $75–$300 million per year for developing new antibiotics that treat drug-resistant infections. Companies apply after FDA approval, and the government pays them annually for up to 10 years, with payments reduced by any sales revenue they earn. The bill also funds hospital stewardship programs and surveillance of antibiotic resistance.
Why we flagged it
The bill's operative mechanism is a direct annual payment to drug makers ($75–$300M/year) conditioned on FDA approval and unmet-need criteria. The public-health purpose (combating antibiotic resistance) is real, but the primary financial beneficiary is the pharmaceutical industry, not patients or the public directly.
What the text implies
- Annual payments are reduced only by actual US sales revenue, not by R&D costs or manufacturing expenses—companies can receive full subsidies even if they earn substantial profit margins on the same drug.
- The bill does not require participating companies to cap prices, limit profits, or guarantee affordability; a company could receive $300M annually while charging patients prohibitive out-of-pocket costs.
- The 'appropriate use plan' requirement (section 399PP, subsection (d)(4)) is advisory and non-binding; companies submit plans but face no penalty for marketing practices that drive overuse or resistance.
- Contract terms extend up to 10 years even if the pathogen is later removed from CDC's threat list, locking in payments regardless of epidemiological changes.
- The Advisory Group includes industry experts and excludes sitting company employees only during their term; the revolving-door risk is high, and the group's scoring methodology (which determines eligibility) is not subject to public rulemaking comment until after the bill is enacted.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill addresses a genuine public-health crisis—antibiotic resistance—by incentivizing development of drugs that markets alone will not fund. However, it transfers substantial public money ($6 billion authorized) to pharmaceutical companies with minimal price controls, weak transparency on how payments are calculated, and no guarantee that subsidized drugs will be affordable or accessible to patients who need them.
Who stands to gain
- pharmaceutical companies developing antimicrobial drugs
- large-cap pharma (Bristol Myers Squibb, Pfizer, Johnson & Johnson, Gilead Sciences)
- smaller biotech firms with antimicrobial pipelines
Named in the bill
U.S. Department of Health and Human Services (HHS/Secretary), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Critical Need Antimicrobial Advisory Group, Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), DaVita (DVA), AMR Industry Alliance, BSI Standards Limited
Where it stands
4 cosponsors: 2 Democrats, 2 Republicans.
- Jun 23, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jun 23, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
6 lobbying clients named this bill on 6 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,280,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 82% of bills with at least one filing.
Michael Bennet, the sponsor, reported $21,000 in PAC receipts in the 2026 cycle.
- National Association of Broadcasters — $2,620,000 on 1 filing
- Cystic Fibrosis Foundation — $270,000 on 1 filing
- Dh Diagnostics, LLC — $220,000 on 1 filing
- Dh Diagnostics LLC — $70,000 on 1 filing
- American Society for Microbiology — $50,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (25,660 characters) on Aug 18, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress to pay pharma $6B for antibiotics—with no price caps” QuorumCivic. https://share.quorumcivic.app/bill/119/s4875 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.